ES2780382T3 - Derivados de pirazolopirimidina - Google Patents

Derivados de pirazolopirimidina Download PDF

Info

Publication number
ES2780382T3
ES2780382T3 ES16717993T ES16717993T ES2780382T3 ES 2780382 T3 ES2780382 T3 ES 2780382T3 ES 16717993 T ES16717993 T ES 16717993T ES 16717993 T ES16717993 T ES 16717993T ES 2780382 T3 ES2780382 T3 ES 2780382T3
Authority
ES
Spain
Prior art keywords
mmol
alkyl
mixture
nmr
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16717993T
Other languages
English (en)
Spanish (es)
Inventor
Asier Unciti-Broceta
Craig Fraser
Carragher Neil O
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Application granted granted Critical
Publication of ES2780382T3 publication Critical patent/ES2780382T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16717993T 2015-05-21 2016-04-15 Derivados de pirazolopirimidina Active ES2780382T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1508747.1A GB201508747D0 (en) 2015-05-21 2015-05-21 Compounds
PCT/GB2016/051057 WO2016185160A1 (en) 2015-05-21 2016-04-15 Compounds

Publications (1)

Publication Number Publication Date
ES2780382T3 true ES2780382T3 (es) 2020-08-25

Family

ID=53506149

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16717993T Active ES2780382T3 (es) 2015-05-21 2016-04-15 Derivados de pirazolopirimidina

Country Status (8)

Country Link
US (1) US10294227B2 (enExample)
EP (1) EP3298015B1 (enExample)
JP (1) JP6684831B2 (enExample)
CN (1) CN107849050B (enExample)
CA (1) CA3021550C (enExample)
ES (1) ES2780382T3 (enExample)
GB (1) GB201508747D0 (enExample)
WO (1) WO2016185160A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190366331A1 (en) * 2016-12-15 2019-12-05 Tunghai University Assay plate and manufacturing method thereof
SI3612519T1 (sl) 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine
WO2020010204A1 (en) * 2018-07-05 2020-01-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
EP3753944A1 (en) * 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments
WO2021041973A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting compounds
KR20220066290A (ko) * 2019-08-29 2022-05-24 히버셀, 인크. Perk 억제 피롤로피리미딘 화합물
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
TW202321248A (zh) 2021-08-11 2023-06-01 愛丁堡大學 酪胺酸激酶抑制劑
JP2024544558A (ja) * 2021-11-15 2024-12-03 ウィゲン・バイオメディシン・テクノロジー・(シャンハイ)・カンパニー・リミテッド Src阻害剤としての化合物
US20250241916A1 (en) 2022-04-07 2025-07-31 Nuvectis Pharma, Inc. Tyrosine kinase inhibitors
WO2025101861A1 (en) * 2023-11-08 2025-05-15 Nuvectis Pharma, Inc. Crystalline forms of the tyrosine kinase inhibitor ecf506
WO2025101874A1 (en) * 2023-11-08 2025-05-15 Nuvectis Pharma, Inc. Crystalline salt forms of the tyrosine kinase inhibitor ecf506

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2011094628A1 (en) 2010-01-28 2011-08-04 University Of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
BR112014029718A2 (pt) * 2012-05-31 2017-06-27 Pharmascience Inc inibidores da proteína quinase
CN105451741A (zh) * 2013-08-06 2016-03-30 福建海西新药创制有限公司 布鲁顿酪氨酸激酶的抑制剂

Also Published As

Publication number Publication date
CA3021550C (en) 2023-10-03
JP6684831B2 (ja) 2020-04-22
US20180127422A1 (en) 2018-05-10
CN107849050B (zh) 2020-10-13
CA3021550A1 (en) 2016-11-24
EP3298015B1 (en) 2020-01-08
CN107849050A (zh) 2018-03-27
JP2018515563A (ja) 2018-06-14
EP3298015A1 (en) 2018-03-28
WO2016185160A1 (en) 2016-11-24
US10294227B2 (en) 2019-05-21
GB201508747D0 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
EP3298015B1 (en) Pyrazolopyrimidine derivatives
ES3044433T3 (en) Compositions for use in a method of treating an estrogen receptor associated cancer
CN114341162B (zh) 作为治疗剂的细胞毒素的肽缀合物
US10577366B2 (en) Crystalline forms of a compound that inhibits bromodomain
ES2360933T3 (es) Derivados de heteroarilo condensados.
WO2020160193A2 (en) Compounds and uses thereof
ES2913048T3 (es) Compuestos heterocíclicos y usos de estos
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
KR20110022589A (ko) 혈관 내피 성장 인자 수용체에 대한 특이적 억제제
CA3172987A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
CA2895162C (en) Methods and compositions for inhibiting cnksr1
BR112015017963B1 (pt) Composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
JP7028643B2 (ja) 膜を破壊しないp53活性化ステープルペプチド
ES2675580T3 (es) 1H-pirazol-5-olato sódico sustituido
CN107531683A (zh) Usp7抑制剂化合物及使用方法
US10501466B2 (en) WDR5 inhibitors and modulators
ES2954453T3 (es) Compuestos de pirimidina y métodos que utilizan los mismos
WO2020028392A1 (en) Niclosamide analogues and therapeutic use thereof
CA2983260C (en) Sulfonamide compounds, compositions and methods for inhibiting cnksr1
CN112010789A (zh) 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
KR20220042136A (ko) 복소 고리 화합물
WO2025184565A1 (en) Targeted protein modification